DarioHealth (DRIO) Projected to Post Quarterly Earnings on Monday

DarioHealth (NASDAQ:DRIO) is expected to post its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect DarioHealth to post earnings of ($1.57) per share and revenue of $5.0480 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 9, 2026 at 8:30 AM ET.

DarioHealth Stock Performance

Shares of DRIO stock opened at $11.97 on Monday. The firm has a 50 day moving average of $11.28 and a two-hundred day moving average of $11.76. The stock has a market capitalization of $80.92 million, a PE ratio of -1.07 and a beta of 1.08. The company has a quick ratio of 4.02, a current ratio of 4.55 and a debt-to-equity ratio of 0.41. DarioHealth has a 52 week low of $5.93 and a 52 week high of $17.74.

Analyst Ratings Changes

A number of research analysts recently issued reports on DRIO shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of DarioHealth in a report on Monday, December 29th. TD Cowen reaffirmed a “hold” rating on shares of DarioHealth in a research report on Friday, November 14th. Wall Street Zen cut DarioHealth from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th. Finally, Stifel Nicolaus set a $16.00 target price on shares of DarioHealth in a research note on Friday, November 14th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $38.00.

Institutional Trading of DarioHealth

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC purchased a new stake in shares of DarioHealth in the 4th quarter valued at about $35,000. Geode Capital Management LLC increased its position in DarioHealth by 167.9% during the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after buying an additional 31,063 shares during the period. Finally, XTX Topco Ltd increased its position in DarioHealth by 229.0% during the second quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after buying an additional 43,513 shares during the period. Institutional investors and hedge funds own 33.39% of the company’s stock.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.